[Asia Economy Reporter Chunhee Lee] GC Green Cross Wellbeing has confirmed the muscle loss inhibition effect of ‘GCWB204,’ a new drug candidate for treating cancer cachexia, a severe systemic wasting caused by cancer, through animal model experiments.
GC Green Cross Wellbeing announced on the 25th that the results of this study, jointly conducted by the research team of Professor Dongcheol Woo from the Department of Convergence Medicine at Seoul Asan Medical Center and GC Green Cross Wellbeing, were recently published in the international journal ‘Metabolomics’.
The research team measured key biomarkers related to the efficacy of GCWB204 in a muscle loss animal model induced by the anticancer drug 5-Fluorouracil, analyzing the inhibitory effects and mechanisms on muscle loss. As a result, the experimental group treated with GCWB204 showed about a 12% reduction in weight loss caused by the anticancer drug. Additionally, a decrease in the activity of the inflammatory biomarker ‘interleukin-6’ was confirmed.
The company evaluated the significance of this study by stating that "GCWB204 not only restores the decreased body weight, muscle mass, and fat mass but also is expected to improve function."
Professor Dongcheol Woo said, “Through this study, we were able to clarify the efficacy of the cancer cachexia treatment drug ‘GCWB204’ and the mechanisms related to key biomarkers, and it is evident that it has sufficient potential as a treatment for various chronic diseases accompanied by weight loss.”
GC Green Cross Wellbeing’s GCWB204 has currently completed Phase 2 clinical trials in Europe targeting patients with gastrointestinal cancer and non-small cell lung cancer, and expects to secure clinical results in the first half of this year. Currently, it is partnering with global pharmaceutical companies aiming for technology transfer.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
